{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:26:19Z","timestamp":1788452779317,"version":"build-2803163510"},"reference-count":44,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2026,2,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Antimicrobial resistance driven by multidrug-resistant (MDR) Gram-negative pathogens poses a major global threat, contributing to substantial morbidity and mortality. Novel \u03b2-lactam\/\u03b2-lactamase inhibitor combinations, particularly meropenem\u2013vaborbactam (M\/V) and ceftazidime\u2013avibactam (C\/A), have expanded therapeutic options; however, their comparative efficacy and safety remain uncertain. This meta-analysis compared M\/V and C\/A in adult patients with MDR Gram-negative infections. MEDLINE, Embase, and Cochrane Central were searched for studies evaluating M\/V versus C\/A in hospitalized adults. Outcomes included all-cause mortality, clinical cure, and microbiological recurrence; safety was assessed qualitatively. Data were synthesized using Review Manager, with trial sequential analysis (TSA) applied to minimize random error. Five retrospective cohort studies (three full articles and two conference abstracts) comprising 3,280 patients were included, of whom 577 received M\/V and 2,703 received C\/A. Populations predominantly consisted of older adults aged 57\u201370 years, with respiratory tract infections being most common. Pooled analyses demonstrated no statistically significant differences between M\/V compared to C\/A in all-cause mortality (Odds ratio [OR] 0.87; 95% CI 0.69\u20131.11;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.26; I\u00b2 = 16%), clinical cure (OR 1.41; 95% CI 0.66\u20133.03;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.37; I\u00b2 = 55%), and microbiological recurrence (OR 0.67; 95% CI 0.32\u20131.40;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.29; I\u00b2 = 0%). Qualitative synthesis indicated comparable tolerability. TSA for mortality demonstrated insufficient evidence for definitive conclusions. M\/V showed no statistically significant difference over C\/A; therefore, selection should be guided judiciously based on clinical context. Further studies are needed to define the optimal role of each agent within antimicrobial stewardship frameworks.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.01546-25","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T14:33:06Z","timestamp":1767709986000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness and safety of meropenem\u2013vaborbactam versus ceftazidime\u2013avibactam in multidrug-resistant Gram-negative infections: a systematic review and meta-analysis with trial sequential analysis"],"prefix":"10.1128","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1483-2550","authenticated-orcid":false,"given":"Shahd","family":"Mohammad","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03gd1jf50","id-type":"ROR","asserted-by":"publisher"}],"name":"Clinical Pharmacy Department, Sheikh Khalifa Medical City","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0828-0265","authenticated-orcid":true,"given":"Yamama","family":"Al Namer","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Sheikh Tahnoon Bin Mohammad Medical City","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1953-5157","authenticated-orcid":true,"given":"Wafaa","family":"Rahimeh","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/023abrt21","id-type":"ROR","asserted-by":"publisher"}],"name":"Clinical Pharmacy Department, College of Pharmacy, Al Ain University","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mosab","family":"Albalas","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Department, Sheikh Tahnoon Bin Mohammad Medical City","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1508-8693","authenticated-orcid":true,"given":"Thamer A.","family":"Almangour","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02f81g417","id-type":"ROR","asserted-by":"publisher"}],"name":"Clinical Pharmacy Department, College of Pharmacy, King Saud University","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare11131946"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.2174\/1871526523666230725103902"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02724-0"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S244357"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01730-17"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000004265"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S518397"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.18433\/J3X31R"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2020.1756775"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.884365"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00115-20"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12101521"},{"key":"e_1_3_4_15_2","unstructured":"Higgins JPT Thomas J Chandler J et al.. 2024. Edited by J. P. T. Higgins J. Thomas and J. Chandler. Cochrane handbook for systematic reviews of interventions. Cochrane. Available from: www.training.cochrane.org\/handbook"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-025-02608-7"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14010029"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02313-19"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae631.104"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2024.10.011"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw282"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.3390\/medsci6010001"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S349004"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14050528"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04218-14"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.01.018"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01935-19"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-020-00344-z"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-023-00762-9"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz522"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-019-02804-z"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-018-0214-1"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01713-15"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","unstructured":"Tiseo G Galfo V Riccardi N Suardi LR Pogliaghi M Giordano C Leonildi A Barnini S Falcone M. 2024. Real-world experience with meropenem\/vaborbactam for the treatment of infections caused by ESBL-producing enterobacterales and carbapenem-resistant Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis. doi:10.1007\/s10096-024-04758-2","DOI":"10.1007\/s10096-024-04758-2"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae273"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-025-00857-8"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01904-17"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy576"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01936-19"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab176"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201667"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01893-6"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25179574"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2025.2465129"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01546-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01546-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T14:01:26Z","timestamp":1770213686000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01546-25"}},"subtitle":[],"editor":[{"given":"Pranita D.","family":"Tamma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,4]]}},"alternative-id":["10.1128\/aac.01546-25"],"URL":"https:\/\/doi.org\/10.1128\/aac.01546-25","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"2025-10-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01546-25"}}